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ABSTRACT
Autosomal dominant hypocalcemia (ADH) is characterized by hypocalcemia, inappropriately low serum parathyroid hormone
concentrations and hypercalciuria. ADH is genetically heterogeneous with ADH type 1 (ADH1), the predominant form, being caused
by germline gain-of-function mutations of the G-protein coupled calcium-sensing receptor (CaSR), and ADH2 caused by germline
gain-of-function mutations of G-protein subunit a-11 (Ga11). To date Ga11 mutations causing ADH2 have been reported in only ﬁve
probands. We investigated a multigenerational nonconsanguineous family, from Iran, with ADH and keratoconus which are not
known to be associated, for causativemutations by whole-exome sequencing in two individuals with hypoparathyroidism, of whom
one also had keratoconus, followed by cosegregation analysis of variants. This identiﬁed a novel heterozygous germline Val340Met
Ga11 mutation in both individuals, and this was also present in the other two relatives with hypocalcemia that were tested. Three-
dimensional modeling revealed the Val340Metmutation to likely alter the conformation of the C-terminal a5 helix, whichmay affect
G-protein coupled receptor binding and G-protein activation. In vitro functional expression of wild-type (Val340) and mutant
(Met340) Ga11 proteins in HEK293 cells stably expressing the CaSR, demonstrated that the intracellular calcium responses following
stimulation with extracellular calcium, of the mutant Met340 Ga11 led to a leftward shift of the concentration-response curve with a
signiﬁcantly (p< 0.0001) reduced mean half-maximal concentration (EC50) value of 2.44mM (95% CI, 2.31 to 2.77mM) when
compared to thewild-type EC50 of 3.14mM (95%CI, 3.03 to 3.26mM), consistentwith a gain-of-functionmutation. A novel His403Gln
variant in transforming growth factor, beta-induced (TGFBI), that may be causing keratoconus was also identiﬁed, indicating likely
digenic inheritance of keratoconus and ADH2 in this family. In conclusion, our identiﬁcation of a novel germline gain-of-function
Ga11 mutation, Val340Met, causing ADH2 demonstrates the importance of the Ga11 C-terminal region for G-protein function and
CaSR signal transduction. © 2016 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc. on behalf of
American Society for Bone and Mineral Research (ASBMR).
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Introduction
Autosomal dominant hypocalcemia (ADH) is a disorder ofsystemic calcium homeostasis that is associated with
enhanced sensitivity of the calcium-sensing receptor (CaSR) to
extracellular calcium (Ca2þo) concentrations.
(1–3) The CaSR is a
guanine-nucleotide binding protein (G-protein)-coupled recep-
tor (GPCR) that plays a pivotal role in Ca2þo homeostasis by
transducing increases in the prevailing Ca2þo concentration into
multiple signaling cascades that include Gq/11-protein–mediated
activation of phospholipase C (PLC), which in the parathyroid
glands and kidneys induces rapid increases in intracellular
calcium (Ca2þi) that lead to decreased parathyroid hormone
(PTH) secretion and increased urinary calcium excretion,
respectively.(2,4,5) ADH is a genetically heterogeneous disorder
most commonly caused by germline gain-of-function muta-
tions of the CaSR, which is encoded by the CASR gene on
chromosome 3q21.1, and this is referred to as ADH type 1
(ADH1; OMIM #601198).(1,2,5) However, some ADH patients and
families have recently been shown to harbor germline
mutations of G-protein subunit-a11 (Ga11), which is encoded
by the GNA11 gene (Fig. 1) on chromosome 19p13.3,(3,6,7) and
referred to as ADH type 2 (ADH2; OMIM #615361).(3) These
ADH-associated Ga11 mutations have been demonstrated to
enhance CaSR-mediated signaling in cellular studies, consis-
tent with a gain-of-function.(3,7) ADH1 patients have calcitropic
phenotypes, such as hypocalcemia with inappropriately low or
normal PTH concentrations and a relative hypercalciuria that is
characterized by urinary calcium to creatinine ratios that are
within or above the reference range,(1,8,9) and mice with a
gain-of-function CaSR mutation, that are representative of
ADH1, have been reported to also have non-calcitropic
phenotypes such as cataracts.(10) Although these features
are similar to hypoparathyroidism, ADH1 is considered to
represent a distinct disease entity from hypoparathyroidism,
because affected individuals generally have PTH concentra-
tions that are detectable and within the reference range.(1,8)
Furthermore, ADH1 patients may also develop a Bartter-like
syndrome characterized by hypokalemic alkalosis, renal salt
wasting, and hyperreninemic hyperaldosteronism,(11,12) and
the use of active vitamin D metabolites to treat symptomatic
ADH1 patients may result in the development of marked
hypercalciuria, nephrocalcinosis, nephrolithiasis, and renal
impairment.(1,9) In contrast to ADH1, the phenotypic spectrum
of ADH2 has not been fully elucidated, especially because only
ﬁve ADH2 probands with Ga11 mutations (Fig. 1) have been
reported to date.(3,6,7) Thus, it remains to be established
whether ADH2 patients with germline gain-of-function Ga11
mutations are susceptible to hypercalciuria, particularly when
treated with active vitamin D preparations, or at risk of a
Bartter-like syndrome. Moreover, Ga11 is a widely expressed
protein that mediates the biological effects of GPCRs in a
range of tissues,(13) and it is currently unknown whether
patients with ADH2 may harbor additional calcitropic and non-
calcitropic phenotypes. We ascertained a family with ADH and
keratoconus, a non-calcitropic disorder of the cornea, and
hypothesized that either a single genetic abnormality may be
causing ADH and keratoconus, or that ADH and keratoconus
may be due to two different genetic abnormalities; ie, digenic
inheritance. To explore these hypotheses, we undertook
whole-exome sequencing (WES) analysis of two relatives,
both of whom had hypocalcemia, and one of whom also had
keratoconus, to identify the causative variant(s).
Patients and Methods
Patients
The proband (individual I.4; Fig. 2A) is a 66-year-old male, from
Iran, who was diagnosed with hypocalcemia at the age of
16 years following a childhood history of intermittent muscle
cramps. His serum adjusted-calcium concentrations have
ranged from 1.82 to 1.95mmol/L (normal range¼ 2.20 to
2.60mmol/L), in association with mild hyperphosphatemia
(serum phosphate¼ 1.42 to 1.81mmol/L; normal range¼ 0.80
to 1.45mmol/L), normal serum creatinine concentrations of
72 to 80 mmol/L (normal range¼ 44 to 133 mmol/L), low/normal
serum PTH concentrations of 4.0 to 18.7 pg/mL (normal
range¼ 12 to 65 pg/mL), a normal 25-hydroxyvitamin D
concentration of 18.7 ng/mL (normal range¼ 10 to 50 ng/mL),
and a normal 1,25-dihydroxyvitamin D concentration of
25.7 pg/mL (normal range¼ 16 to 45 pg/mL). He had been
treated with oral calcium and active vitamin D preparations, and
developed non-obstructive bilateral nephrolithiasis in associa-
tion with urinary calcium values ranging from 4.3 to 10.2mmol/
24 hours (normal range¼ 2.5 to 7.5mmol/24 hours). He was
found to have mild bilateral cataracts at the age of 62 years. His
family history revealed that 11 relatives (7 males and 4 females)
over three generations had hypocalcemia, with symptoms
such as seizures, muscle cramps, and tetany. Affected relatives
also had low circulating PTH concentrations, and relative or
absolute hypercalciuria (Fig. 2A), and these ﬁndings supported a
diagnosis of ADH. Five hypocalcemic family members (3 males
and 2 females) and one normocalcemic family member also had
keratoconus, a corneal disorder, which in individuals II.3, II.5,
and II.7 (Fig. 2A) had developed between the ages of 30 and
34 years.(14) There was no consanguinity and the inheritance of
hypocalcemia from father to son in individuals; eg, from I.1 to II.1
and II.2; I.4 to II.5; and II.5 to III.1 (Fig. 2A), indicated that
hypocalcemia was transmitted as an autosomal dominant
Fig. 1. Schematic representation of the genomic organization of the
human GNA11 gene showing the location of ADH2-causing mutations.
The GNA11 gene consists of 7 exons with the start (ATG) and stop (TGA)
codons located in exons 1 and 7, respectively. The GTPase domain
(encoded by exon 1, 50 portion of exon 2, 30 portion of exon 4 and exons
5 to 7) is connected to the helical domain (encoded by the 30 portion of
exon 2, exon 3, and 50 portion of exon 4) by the linker 1 (L1) and linker 2
(L2) peptides. The previously reported ADH2-causing Arg60Cys (R60C),
Arg60Leu (R60L), and Arg181Gln (R181Q) mutations(3,6,7) are located at
the interface between the helical and GTPase domains and adjacent to
the linker peptides. The reported ADH2-causing Ser211Trp (S211W)
mutation is located in the a2 helix of the GTPase domain;(6) and the
Val340Met (V340M) mutation reported by this study (shown in bold),
and the previously reported Phe341Leu (F341L) mutation(3) are located
in the a5 helix of the GTPase domain. Coding-regions are shaded gray
and untranslated regions are represented by open boxes.
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disorder. Similarly, the inheritance of keratoconus from father to
son in individuals II.5 to III.1 (Fig. 2A), may be because
keratoconus is transmitted as an autosomal dominant disorder,
but the occurrence of keratoconus in the children (II.3, II.5
and II.7; and II.8) of unaffected parents (I.4 and I.5; and I.8 and
I.9, respectively, Fig. 2A) indicates an autosomal recessive
inheritance or autosomal dominant inheritance with reduced
penetrance. To investigate the cause of the hypocalcemia
and keratoconus in this family, venous blood samples were
collected from four available patients, of whom two had
hypocalcemia only (individuals I.4 and II.4), and two others had
both hypocalcemia and keratoconus (individuals II.3 and II.5;
Fig. 2A). Leukocyte DNA was extracted using the Gentra
PureGene blood kit (Qiagen, Crawley, UK). CaSR mutations,
which would cause ADH1, and mutations of three genes, GCMB,
PTH, and AIRE1, which are known to cause hypoparathyroidism
had been previously excluded by an accredited genetics
diagnostic laboratory. Informed consent was obtained from all
participants included in the study, using protocols approved by
the UK Multicentre Research Ethics Committee (MREC/02/2/93)
and the Hospital Research Ethics in Israel.
Exome capture and DNA sequence analysis
Exome capture was performed in individual I.4, who was
affected with hypocalcemia, and in individual II.5, who was
affected with both hypocalcemia and keratoconus (Fig. 2A),
using the SeqCap EZ Human Exome Library v2.0 (Roche
NimbleGen, Madison, WI, USA),(15) and DNA sequences
determined using a 100-bp paired-end read protocol on an
Illumina HiSeq2000 platform.(15) Aminimumof 20 vertical read
depth was obtained for>88% of the coding exome, as speciﬁed
by the consensus coding sequence (CCDS) project,(16) in both
individuals. Reads were aligned to the Human Sequence version
37d5 (hs37d5) reference genome using Stampy(17) and variant
calling of single nucleotide variants (SNVs) and short insertions
and deletions (indels) was undertaken using Platypus (v0.5.1).(18)
Analysis of coding variants was undertaken using Ingenuity
Variant Analysis. To search for variants causing hypocalcemia
and keratoconus under autosomal dominant inheritance
models, variants with a minor allele frequency (MAF) >5%
within all populations of 100 genomes data (April 2012 phase
1 call set [v3 update]) and from the National Heart, Lung, and
Blood Institute (NHLBI) exome sequencing project (Exome
Variant Server, NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA (http://evs.gs.washington.edu/EVS/), were ex-
cluded. To search for variants causing keratoconus under an
autosomal recessive inheritance model, variants with a MAF
>5% were not excluded. The pathogenicity of variants was
inferred from several criteria: allele frequency within the
NHLBI exome sequencing project and the Exome Aggregation
Consortium (ExAC) (Cambridge, MA, USA; http://exac.
broadinstitute.org/), amino acid conservation, physicochemi-
cal alterations in amino acid substitutions, splice site
prediction algorithms (NNSPLICE [http://www.fruitﬂy.org/seq_
tools/splice.html], MaxEntScan [http://genes.mit.edu/burgelab/
maxent/Xmaxentscan_scoreseq.html], GeneSplicer [http://
www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml],
Fig. 2. Identiﬁcation of a Val340Met Ga11 mutation in a family with hypocalcemia and keratoconus. (A) Pedigree of the family, with males and females
indicated by squares and circles, respectively. Individuals affected with hypocalcemia, keratoconus, or the combined occurrence of hypocalcemia and
keratoconus are indicated by left half-ﬁlled, right half-ﬁlled, or ﬁlled symbols, respectively, and unaffected individuals are indicated by open symbols. The
proband (individual I.4) is indicated by an arrow, and asterisks indicate those individuals fromwhomDNAwas available for these studies. Plasma calcium
(Ca) (mmol/L; normal range¼ 2.20 to 2.60mmol/L) and plasma PTH (pg/mL; normal range¼ 12 to 65 pg/mL) values are shown for individuals I.4, II.3, II.4,
and II.5. (B) A heterozygous G>A transition at nucleotide c.1018 within exon 7 of GNA11 (Fig. 1) was identiﬁed by WES and conﬁrmed by Sanger
DNA sequence analysis. The c.1018G>A GNA11 variant was detected in all four family members with hypocalcemia from whom samples were available.
(C) This DNA sequence abnormality was predicted to lead to a missense amino acid substitution of Val to Met at codon 340.
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and SpliceSiteFinder-Like [http://www.interactive-biosoftware.
com]), and literature review. Variants of interest were
conﬁrmed by polymerase chain reaction (PCR) and Sanger
DNA sequence analysis of the appropriate exons, using
leukocyte DNA samples from the four available family
members and two unrelated unaffected individuals, as
reported.(19)
Protein sequence alignments and three-dimensional
modeling
Amino acid sequences of Ga-subunit paralogs and transforming
growth factor, beta-induced (TGFBI) orthologs were aligned
using the Clustal Omega program (European Bioinformatics
Institute, the European Molecular Biology Laboratory). The
crystal structure of Gaq in complex with the GTP analogue
guanosine diphosphate (GDP)-AIF4 has been determined
(Protein Data Bank [PDB] accession number 3OHM),(20) and
this was used tomodel Ga11, which has 90% identity with Gaq at
the amino acid level, using the PyMOL Molecular Graphics
System (version 1.2r3pre; Schrodinger, LLC).
Cell culture and transfection
The generation of wild-type and mutant Leu341 pBI-CMV2-
GNA11 expression constructs have been reported.(3) Site-
directed mutagenesis was used to generate the Val to Met
mutation at codon 340 in the pBI-CMV2-GNA11 construct using
the Quikchange Lightning Site-directedMutagenesis kit (Agilent
Technologies, Santa Clara, CA, USA) and gene-speciﬁc primers
(SigmaAldrich, St Louis, MO, USA), as reported.(19) For all studies,
empty vector, wild-type, or mutant pBI-CMV2-GNA11 expression
constructs were transiently transfected into human embryonic
kidney (HEK) 293 cells stably expressing the CaSR (HEK293-CaSR)
using Lipofectamine 2000 (LifeTechnologies, Carlsbad, CA,
USA).(21) Cells were maintained in DMEM-Glutamax media
(ThermoFisher, Waltham, MA, USA) with 10% fetal bovine serum
(Gibco, Carlsbad, CA, USA) and 400mg/mL geneticin (Thermo-
Fisher) at 37°C, 5% CO2. Successful transfection was conﬁrmed
by visualizing GFP ﬂuorescence using an Eclipse E400 ﬂuores-
cence microscope with a Y-FL Epiﬂuorescence attachment and a
triband 4,6-diamidino-2-phenylindole-FITC-Rhodamine ﬁlter,
and images captured using a DXM1200C digital camera and
NIS Elements software (Nikon).(3,21,22) The expression of Ga11,
GFP, calnexin, and CaSR proteins was also determined by
Western blot analysis using anti-Ga11 (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA), anti-GFP (Santa Cruz), anti-calnexin
(Millipore, Billerica, MA, USA), or anti-CaSR (Abcam, Cambridge,
UK) antibodies. The Western blots were visualized using
Immuno-Star WesternC kit (BioRad, Hercules, CA, USA) on a
BioRad Chemidoc XRSþ system.(3)
Intracellular calcium measurements
The Ca2þi responses of HEK293-CaSR cells expressing wild-type or
mutant Ga11 proteins were assessed by a ﬂow cytometry–based
assay, as reported.(2,3,21,22) In brief, HEK293-CaSR cells were plated
in T75 ﬂasks and transiently transfected 24 hours later with 16mg
DNA.(3) At 48 hours posttransfection, cells were detached,
resuspended in calcium (Ca2þ)-free and magnesium (Mg2þ)-free
Hanks buffered saline solution (HBSS) and loaded with 1mg/mL
Indo-1-acetoxymethylester (Indo-1-AM) for 1 hour at 37°C. After
removal of free dye, the cells were resuspended in Ca2þ-free and
Mg2þ-free HBSS and maintained at 37°C. Transfected cells, in
suspension, were analyzed by ﬂow cytometry on aMoFlomodular
ﬂow cytometer (Beckman Coulter, Indianapolis, IN, USA) and data
on the Ca2þi responses to alterations in Ca
2þ
o collected from all
cells that expressed GFP, by simultaneous measurements of GFP
expression (at 525nm), Ca2þi-bound Indo-1AM (at 410nm), and
free Indo-1AM (ie, not bound to Ca2þi) (at 485nm), using a JDSU
Xcyte laser (Coherent Radiation, Santa Clara, CA, USA), on each cell
at eachCa2þo concentration [Ca
2þ]o, asdescribed.
(3,21) Assayswere
performed in four biological replicates for each of the expression
constructs. The peak mean ﬂuorescence ratio of the transient
response after each individual stimulus was measured using
CytomationSummit software (BeckmanCoulter), andexpressedas
a normalized response, as described.(3,21) Nonlinear regression of
concentration-response curves was performed with GraphPad
Prism using the normalized response at each [Ca2þ]o for each
separate experiment for the determination of the EC50 (ie, [Ca
2þ]o
required for 50% of the maximal response). Data is presented
as mean with conﬁdence interval or mean standard error of
the mean (SE). Statistical analysis was performed using the
F-test. A value of p < 0.05 was considered signiﬁcant for all
analyses.
Results
Identification of a novel Val340Met Ga11 mutation
Exome capture and high-throughput sequence analysis of
genomic DNA from two affected individuals, one with hypocalce-
mia (individual I.4) and the other with hypocalcemia and
keratoconus (individual II.5) (Fig. 2A) resulted in the detection of
>5000 non-dbSNP variants in both individuals. The exclusion of
variants with a MAF of >5% resulted in the identiﬁcation of 104
novel variants in 103 genes, of which three variants were excluded
as sequence artifacts as they occurredwithin trinucleotide repeats.
The only variant identiﬁed in a gene previously associated with
hypocalcemia, was a heterozygous G>A transition at nucleotide
c.1018 (c.1018G>A), located in exon 7 of the GNA11 gene (Fig. 1).
The variant was conﬁrmed by Sanger DNA sequencing to be
present in both patients affected with hypocalcemia (individuals
I.4 and II.5) and in two other family members (individuals II.3
and II.4) with hypocalcemia from whom samples were available
(Fig. 2B). This G>A transition (GTG to ATG) resulted in a missense
substitution, Val340Met, of the encoded Ga11 protein (Fig. 2C).
The absence of this DNA sequence abnormality in >60,000
exomes fromtheExomeAggregationConsortium(ExAC), together
with evolutionary conservation of the Val340 residue in vertebrate
Ga-subunit paralogs (Fig. 3A) indicated that the Val340Met
abnormality likely represented a pathogenic GNA11 mutation
rather than a benign polymorphic variant.
Identification of candidate variant for keratoconus
Whole-exome sequencing revealed a novel heterozygous
c.1209T>G transversion in TGFBI, encoding a variant His403Gln
in TGFBI, which was present in both individuals (I.4 and II.5,
Supporting Fig. 1A, Supporting Table 1). The TGFBI His403Gln
variant is not present in ExAC, although a different variant in the
same amino acid, His403Tyr, is present in only 3 out of >60,000
individuals. The His403 residue is also evolutionarily conserved
in TGFBI orthologs (Supporting Fig. 1B). The TGFBI variant was
conﬁrmed by Sanger DNA sequence analysis in the siblings, II.3
and II.5, who had hypocalcemia and keratoconus, but its
absence in the sister II.4, who has hypocalcemia only, indicates
that this TGFBI variant is not involved in the etiology of
hypocalcemia (Supporting Fig. 1A). Moreover, the presence of
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this TGFBI variant in the father (individual I.4), who was affected
with hypocalcemia only, indicates likely nonpenetrance of the
mutant allele (Supporting Fig. 1A).
Structural characterization of the Val340Met Ga11
mutant protein
To evaluate whether the Val340Met GNA11 variant represents a
pathogenic mutation and the cause of hypocalcemia in this
family, structural and functional studies were undertaken. The
crystal structure of Gaq, which shares 90% amino acid identity
with Ga11,
(3,20) was used to predict the effects of the Val340Met
mutation. The mutated Val340 residue is located within the a5
helix of the GTPase domain of Ga11 (Fig. 3B, C), and next to the
Phe341 residue, which has been reported to be associated
with a gain-of-function Phe341Leu mutation (Figs. 1 and 3B)
causing ADH2.(3) The a5 helix is located at the C-terminus of
Ga-subunits and plays a critical role in GPCR binding and
G-protein activation.(23,24) Indeed, the C-terminal portion of the
a5 helix, which is known as the interface module, directly binds
to the transmembrane domain and intracellular loops of
activated GPCRs,(24) whereas the N-terminal portion, which is
known as the transmission module, interacts with the GTPase
domain b-sheet, comprising the b1-b6 strands (Fig. 3C), to
mediate conformational changes in Ga-subunit structure that
facilitate guanine nucleotide exchange.(23,25) The Val340 residue
is predicted to form non-polar interactions with the conserved
Phe272 and His327 residues, located in the b5 and b6 strands,
respectively (Fig. 3C), which are considered to stabilize the
binding of G-protein with ligand-bound GPCR.(23,25,26) The
Val340Met mutation is predicted to impair the interaction with
the His327 Ga11 residue (Fig. 3D), thereby altering the
conformation of the a5 helix and/or b6 strand, and destabilizing
the Ga-GPCR complex.
Fig. 3. Predicted effects of the Val340Met mutation on the Ga11 protein. (A) Multiple protein sequence alignment of residues comprising the a5 helix of
Ga-subunit paralogs. The wild-type Val340 (V) andmutant Met340 (M) residues are shown in bold. Conserved residues are shaded gray. (B) Overall three-
dimensional structure of the Ga11 protein. The Ga-subunit helical (blue) and GTPase (green) domains are connected by the L1 and L2 peptides (gray). The
four Ga11 residues, which have been previously reported to be mutated in ADH2,
(3,6,7) are shown in magenta. The mutated Arg60 and Arg181 residues
are located at the interdomain interface (red dashed line), which forms a pocket for the binding of guanine nucleotides (yellow). The GTPase domain is
the location of the mutated Ser211 residue (a2 helix), and mutated Val340 (red) and Phe341 residues (a5 helix). (C) Close-up view of the a5 helix, which
comprises a C-terminal interface module (pink) that interacts with partner GPCRs and an N-terminal transmission module (purple), which interacts with
the surrounding b1-b6 strands to facilitate conformational changes that lead to guanine nucleotide exchange and Ga-subunit activation.(23) The wild-
type Val340 residue (red) is predicted to form non-polar interactions with the Phe272 and His327 residues (cyan), (26) which are located in the b5 and b6
strands, respectively. (D) The introduction of amutantMet340 residue (red, space ﬁllingmodel) is predicted to sterically hinder His327 (cyan, stickmodel),
thereby altering the conformation of the a5 helix and/or b6 strand.
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Functional characterization of the Val340Met Ga11
mutant protein
To determine the effects of these predicted changes in Ga11
structure (Fig. 3) on CaSR-mediated signaling, bidirectional
pBI-CMV2-GNA11 expression constructs containing wild-type
Val340, mutant Met340, or the previously reported gain-of-
function Leu341 mutant GNA11 cDNA,(3) or vector containing
the GFP reporter gene alone were transiently transfected into
HEK293 cells stably expressing the CaSR. Expression of CaSR,
Ga11, and GFP was conﬁrmed by ﬂuorescence microscopy and/
or Western blot analysis (Fig. 4A, B). Calnexin was used as a
Fig. 4. Functional characterization of wild-type and ADH2-associated mutant Ga11 proteins. (A) Fluorescence microscopy of HEK293 cells stably
expressing CaSR (HEK293-CaSR) and transiently transfected with wild-type (WT) or ADH2-associated mutant (m) (Met340 and Leu341) pBI-CMV2-GNA11
constructs, or with vector (V) only. Detection of GFP in these cells indicates successful transfection and expression of these constructs. Bar indicates 10
mm. (B) Western blot analysis of whole-cell lysates using antibodies to CaSR, calnexin, Ga11, and GFP. Transient transfection of WT or ADH2-associated
mutant constructs resulted in overexpression of Ga11 when normalized to calnexin expression. (C) Concentration-response curves showing normalized
Ca2þi response to changes in [Ca
2þ]o of HEK293-CaSR cells transfected with WT or ADH2-associated Ga11 mutants. The Ca
2þ
i responses are shown as the
mean SEM of 4 independent transfections. The ADH2-associated Ga11 mutants (Met340 and Leu341) led to a leftward shift of the concentration-
response curves (blue and red, respectively) when compared with WT Ga11 (black), which harbors Val and Phe residues at codons 340 and 341,
respectively. (D) TheMet340 and Leu341mutants (blue and red bars, respectively) were associated with signiﬁcantly decreased EC50 values compared to
cells expressing WT Ga11 (black bar). p< 0.0001.
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loading control in Western blot analyses, and Ga11 expression
was demonstrated to be similar in cells transiently transfected
with wild-type or mutant Ga11 proteins, and greater than that of
cells transfected with the empty pBI-CMV2 vector (Fig. 4B). The
responses of [Ca2þ]i to alterations in [Ca
2þ]o in cells expressing
the different GNA11 vectors were assessed by ﬂow cytometry.
The Ca2þi responses in wild-type and mutant Ga11-expressing
cells were shown to increase in a dose-dependent manner
following stimulation with increasing concentrations of Ca2þo
between 0 and 15mM. However, expression of the Met340 and
Leu341 mutant Ga11 proteins resulted in a leftward shift of the
concentration-response curves (Fig. 4C), with signiﬁcantly
lower half maximal (EC50) values, compared to wild-type
Val340 Ga11 and empty vector (Met340¼ 2.44mM [95% CI,
2.31 to 2.77mM]; Val340¼ 3.14mM [95% CI. 3.03 to 3.26mM];
empty vector¼ 3.12mM [95% CI, 2.99 to 3.25mM]; p< 0.0001)
(Fig. 4D). There was no signiﬁcant difference in the EC50 values
between Met340 and Leu341 (Leu341¼ 2.60mM; 95% CI, 2.49
to 2.72mM; p > 0.05). Thus, the Val340Met missense substitu-
tion represents a novel gain-of-function Ga11 mutation, similar
to those reported in ADH2 patients.(3,7)
Discussion
The identiﬁcation of a germline gain-of-function Ga11 mutation,
Val340Met, indicates ADH2 tobe the likely cause of hypocalcemia
in this family. To date, ﬁve other hypocalcemic patients and
families have been reported to harbor germline Ga11 mutations,
consistent with a diagnosis of ADH2.(3,6,7) Similar to the family
characterized in this study, individuals with germline gain-of-
function Ga11 mutations have been reported to generally have
mild-to-moderate hypocalcemia (serum adjusted-calcium con-
centrations ranging from 1.75 to 2.15mmol/L) in associationwith
serum PTH concentrations that are detectable and within the
lower half of thenormal range.(3,6,7) However, despiteADH2being
associated with mild biochemical features, affected individuals
are commonly symptomatic and may present with paresthesia,
muscle cramps, carpo-pedal spasms, or seizures.(3,6,7) Moreover,
as described for the proband in this study (individual I.4, Fig. 2A),
some ADH2 patients appear susceptible to treatment-related
hypercalciuria, nephrocalcinosis, and nephrolithiasis,(7) although
affected individuals likely have a milder urinary phenotype, with
signiﬁcantly reduced urinary calcium excretion compared to
ADH1 patients who harbor gain-of-function CaSR mutations.(7)
Furthermore, patients with germline heterozygous gain-of-
function Ga11 mutations, in contrast to patients with germline
heterozygous gain-of-function CaSR mutations, may have non-
calcitropic phenotypes. For example, short stature caused by
postnatal growth insufﬁciency was reported in affected individu-
als from a multigenerational kindred with hypocalcemia and a
germline heterozygous gain-of-function mutation, Arg60Leu,(7)
and it is possible that the occurrence of mild bilateral cataracts in
the proband (individual I.4) may also be due to the germline gain-
of-function Ga11 mutation, Val340Met. It is also of interest to
note that somatic Ga11 mutations that lead to constitutive
G-protein activation are associated with the development of
uveal melanomas.(27) However, keratoconus, a corneal disorder,
was not observed in all patients harboring the germline
Val340Met Ga11 mutation, thereby indicating that keratoconus
is not due to the Ga11 mutation. Instead, keratoconus in this
family is likely due to the identiﬁed novel germline variant,
His403Gln in TGFBI (Supporting Fig. 1), abnormalities of which
have previously been reported in association with keratoconus
and autosomal dominant forms of corneal dystrophy.(28,29) Thus,
the occurrence of keratoconus and ADH2 in this family are not
genetically associated, but are instead due to digenic inheritance
of mutations involving TGFBI and Ga11.
Structural and functional studies of ADH2-causing gain-of-
function Ga11 mutations have revealed residues and peptide
motifs critical for Ga-subunit function. Thus, the importance of
the interface at which the Ga-subunit helical and GTPase
domains interact to mediate guanine nucleotide exchange, has
been demonstrated by the reported Arg60Leu, Arg60Cys, and
Arg181Gln Ga11 mutations,
(3,6,7) which are located at the
interdomain interface (Fig. 3B), (25) and predicted to disrupt
GDP binding.(3,6,7) Whereas, the reported ADH2-causing
Ser211Trp mutation, located in the a2 helix of the GTPase
domain (Fig. 3B), may cause a gain-of-function by dissociating
the Ga-subunit from the Gbg heterodimer.(6) Furthermore, the
reported ADH2-causing Phe341Leu mutation(3) is located in the
C-terminal a5 helix, which facilitates G-protein-GPCR cou-
pling,(23) and the mutated Phe341 residue is predicted to play
major roles in G-protein activation and inactivation.(25,26) Indeed,
under basal conditions, Phe341 forms part of a hydrophobic
cluster of phenylalanine residues that maintains the Ga-subunit
in an inactive GDP-bound conformation.(25,26) Upon ligand-
binding, Phe341 binds to the second intracellular loop of the
activated cognate GPCR,(24) which disrupts the hydrophobic
cluster, leading to the release of GDP.(25,26) The Phe341Leu
mutation is predicted to affect the hydrophobic cluster,(3)
thereby leading to GDP/GTP exchange and G-protein activation.
In contrast to these roles of Phe341, the neighboring Val340
residue does not bind to activated GPCRs and is not involved
in GDP/GTP exchange,(24,25) but instead may play a role in
stabilizing the nucleotide-free conformation of the Ga-subunit
once bound to activated GPCR.(23) Thus, the Val340Metmutation
likely mediates Ga11 activation by inﬂuencing the stability of
Ga-GPCR interactions. These different ADH2 mutations have
yielded insights into Ga-subunit structure-function relation-
ships, which may aid the design of novel targeted therapeutic
agents for the treatment of ADH, for which there is currently a
lack of adequate drugs.(30)
In conclusion, we have identiﬁed a novel germline gain-of-
functionGa11mutation, Val340Met, that causes ADH2 in a family
in which some members also suffered from keratoconus.
Keratoconus in this family was likely due to a novel germline
TGFBI His403Gln variant, thereby indicating that keratoconus
and ADH2 are not caused by the samemutation, but instead the
combined occurrence of ADH2 and keratoconus in some family
members is due to digenic inheritance. Finally, our study
provides an exemplar of the clinical utility of WES, that enabled
the identiﬁcation of two likely genetic causes by a single
experimental protocol, which would not have been readily
possible using former genetic techniques.
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